The FDA has approved Olumiant (baricitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata.

The FDA has approved Olumiant (baricitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata.

Prior to Olumiant, no drug was specifically approved by the FDA for alopecia areata. The traditional treatment has been monthly steroid injections.

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

INDIANAPOLIS, March 26, 2022 /PRNewswire/ -- Adults with severe alopecia areata (AA) who took OLUMIANT® (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% ...

The FDA has approved Olumiant, the first systemic medication for the treatment of alopecia areata, according to a press release. Olumiant (baricitinib, Eli Lilly/Incyte) is a once-daily oral Janus ...

Alopecia areata is an autoimmune disorder in which the body attacks hair follicles, leading to hair loss. The drug, Olumiant, works by interrupting some of the body's misguided messages.

In June 2022, Olumiant ® (baricitinib) was approved by the U.S. Food and Drug Administration (FDA) as the first and only oral treatment for adults with severe alopecia areata.

Alopecia areata is an autoimmune disorder that causes circular patches of hair loss and can result in complete loss scalp, facial and body hair.

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market lead over Litfulo.Exton ...

Patients with alopecia areata had a higher prevalence of autoimmune and psychiatric comorbidities at diagnosis and an increased risk of new onset of these comorbidities after their diagnosis ...